Lesson 6: Course Wrap-up
Congratulations!
You have completed the course entitled "Key Drug Pipeline Databases on Dialog." We hope that you have enjoyed working through the course in your own time.
In this course, we have explored in detail a comprehensive group of pipeline databases.
- In Lesson 1 you reviewed the types of information you would find in pipeline files.
- In Lessons 2-4, you took an in-depth look at key pipeline databases: IMS R&D Focus, Pharmaprojects, and Adis R&D Insight.
- In Lesson 5 you explored several of the Prous family of databases: Prous Science Daily Essentials, Prous Science Drug Data Report, and Prous Science Drugs of the Future.
The following table will provide you with information regarding how and why you might use these pipeline databases in your own investigations.
| How: Database Access Points | Why: Sample Applications | Examples |
|---|---|---|
| Product names |
Access future competition. | Locate summary information on a specific product cited in the printed literature or mentioned at a scientific conference. |
| Prepare for more effective marketing. | What do preliminary results from phase II-III trials tell us about the efficacy and side effects of product X compared to our own? | |
| Company names |
Gauge the earning potential of a given company. | Do the number and types of compounds that corporation Z currently has in clinical trials support its long-term sales predictions? How does it compare with multinational A? |
| Audit research efforts in the context of the competition through periodic benchmarking. | How does this company’s pipeline compare to that of others? | |
| Drug categories |
Focus drug discovery efforts for a more rapid return on investment. | What types of compounds show the most promising
results in this therapeutic area?
What mechanisms of action are leading to more, and faster, drug launches? |
| Extend the commercial life of a patent portfolio. | What does a survey of drugs with this type of
biological activity show, in terms of possible therapeutic
applications?
Can we identify opportunities for expanding the scope of clinical investigations to garner new sources of revenue from our compounds already in the pipeline? |
|
| Developmental stage/ Regulatory status indicators |
Plan for successful and strategic, product launches. | Why are products comparable to our own likely to reach the market at about the same time? |
| Verify time-to-market projections. | Do historical milestone data support our timeline projections? | |
| Assess development speed relative to competitors. | Can we determine chronological norms for progression through each stage for this type of product? | |
| Target markets — Countries | Identify windows of opportunity in the marketplace. | Is there an opportunity for us to launch first in a market not targeted by others? |
| Anticipate competitive challenges. | What comparable products will be introduced in this country at about the same time? |
Go to the next page.
6-1
